{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-024981","form_type":"8-K","ticker":"DNA","cik":"0001830214","company_name":"Ginkgo Bioworks Holdings, Inc.","filed_at":"2022-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.489699+00:00","generated_at":"2026-06-21T21:09:54.854871+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Ginkgo Q3 rev down 14% to $66M; raises FY22 revenue guidance to $460-480M","bullets":["Total revenue $66M (down 14% YoY); Foundry $25M (down 29%), Biosecurity $42M (down 3%).","Operating loss $(653)M includes $563M stock-based comp; Adj EBITDA $(70)M vs $(18)M prior year.","Added 15 new Cell Programs (50% growth); cash & equivalents over $1.3B.","Completed Zymergen, Bayer West Sac, Altar, and Circularis acquisitions in October.","FY22 guidance raised: total rev $460-480M (from $425-440M), Biosecurity at least $310M."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-024981","json":"https://secwatch.observer/filing/0000950170-22-024981.json","markdown":"https://secwatch.observer/filing/0000950170-22-024981.md","text":"https://secwatch.observer/filing/0000950170-22-024981.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1830214/000095017022024981/0000950170-22-024981-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1830214/000095017022024981/dna-20221114.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T21:09:54.854871+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b61c92f0bff164a36c7ee66a61f0d7ad0b3121cd","claim":"Ginkgo Bioworks Holdings, Inc. reported third quarter ended September 30, 2022 results: revenue Third quarter 2022 Total revenue of $66 million.","evidence_excerpt":"Third quarter 2022 Total revenue of $66 million, down from $78 million in the comparable prior year period, a decrease of 14%","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1830214/000095017022024981/0000950170-22-024981-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2022"},{"label":"Revenue","value":"Third quarter 2022 Total revenue of $66 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"c5af1b114392f152e6d30563beafb2e919b98107","claim":"Ginkgo Bioworks Holdings, Inc. reported full year 2022 results: revenue $460 – $480 million. Guidance raised.","evidence_excerpt":"Ginkgo further revised its expectation for Total revenue from $425 – $440 million to $460 – $480 million in 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1830214/000095017022024981/0000950170-22-024981-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year 2022"},{"label":"Revenue","value":"$460 – $480 million"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}